方法：选取2012-01/2014-12我院眼科收治的51例62眼新生血管性青光眼患者为研究对象，在统一入组条件、统一测量方法的前提下，按目前实际诊疗状况并结合医生的判断进行分组，对照组23例28眼，观察组28例34眼。观察组患者接受雷珠单抗注射联合Ex-PRESS引流器植入术，对照组患者单纯给予Ex-PRESS引流器植入术。比较两组患者治疗前后视力水平及眼压，同时比较两组治疗有效率及不良反应发生率。

结果：治疗前，两组患者眼压比较，差异无统计学意义(P>0.05)。治疗后，两组患者眼压均显著降低，组内比较差异有统计学意义(P<0.05)，且观察组治疗后1、4wk时眼压显著低于对照组，组间比较差异有统计学意义(P<0.05)。治疗前，两组视力分布比较，差异无统计学意义(P>0.05)。治疗后，对照组视力升高2例3眼，维持平稳18例22眼，下降3例3 眼； 观察组视力提高12例12眼，维持平稳15例21眼，下降1例1眼，两组视力分布比较差异有统计学意义(P<0.05)。观察组治疗有效率为85.3%，对照组为60.7%，观察组高于对照组，两组比较差异有统计学意义(P<0.05)。观察组前房出血4例4眼，角膜内皮功能失代偿2例2眼，术后并发症发生率为18%； 对照组角膜水肿3例3眼，术后并发症发生率为11%，两组比较差异无统计学意义(P>0.05)。

结论：对于新生血管性青光眼患者，采用雷珠单抗注射联合Ex-PRESS引流器植入术能够有效降低眼压、改善视功能或者延缓患者视功能衰退，具有疗效确切、安全性高等特点，值得临床上推广应用。

METHODS: From January 2012 to December 2014 in our hospital, 51 cases(62 eyes)with neovascular glaucoma were enrolled as the research objects. Under the unified enrolling criteria and measuring methods, according to the actual clinical situation and combined with the doctor's judgment, the patients were divided into control group with 23 cases(28 eyes)and observation group with 28 cases(34 eyes). The patients in observation group received the injection of ranibizumab combined the Ex-PRESS drainage device implantation. The patients in control group were only given the Ex-PRESS drainage device implantation. The vision, intraocular pressure(IOP)before and after treatments were compared as well as the outcomes and incidences of adverse reactions of the two groups.

RESULTS: Before treatments, IOP of the two groups did not have statistically significant different(P>0.05). After treatments, IOP of the two groups were significantly lower, and the differences were statistically significant(P<0.05), and the IOP of the observation group at 1, 4wk after treatments were significantly lower than those of the control group, and the differences were statistically significant(P<0.05). Before treatments, the visual acuity of the two groups did not have statistically significant difference(P>0.05). After treatments, the visual acuity of the control group improved in 2 cases(3 eyes), didn't change in 18 cases(22 eyes), and declined in 3 cases(3 eyes). While the visual acuity of observation group improved in 12 cases(12 eyes), didn't change in 15 cases(21 eyes), and declined in 1 case(1 eye). The distribution of the visual acuity of the two groups was significantly different(P<0.05). The effective rate of observation group was 85.3%, and that of control group was 60.7%. The difference between the two groups was statistically significant(P<0.05). In the observation group, there were 4 cases(4 eyes)with hyphema, 2 cases(2 eyes)with decompensation of corneal endothelial function and the incidence of postoperative complications was 18%. In the control group, there were 3 cases(3 eyes)with corneal edema and the incidence of postoperative complications was 11%. There was no statistically significant difference on the incidence of postoperative complications between the two groups(P>0.05).

CONCLUSION: For patients with neovascular glaucoma, the injection of ranibizumab combined with the Ex-PRESS the drainage device implantation can effectively reduce IOP, improve visual function in patients with impaired visual function or delay the recession of visual function, with outstanding curative effect, high security features and is worthy of clinical application.